Summary.
It has been proposed that excitotoxic damage by glutamatergic hyperactivity is responsible for neurodegeneration in Alzheimer's disease. Lamotrigine (LTG) inhibits presynaptic glutamate release and is considered to be effective in treatment of other neurodegenerative disorders by its cerebroprotective properties. We used LTG in 11 patients with the diagnosis of probable Alzheimer's disease. 300 mg/day administration of LTG improved word recognition, naming and depressed mood on Alzheimer Disease Assessment Scale (ADAS).
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Accepted January 20, 1998; received January 27, 1997
Rights and permissions
About this article
Cite this article
Tekin, S., Aykut-Bingöl, C., Tanrıdağ, T. et al. Antiglutamatergic therapy in Alzheimer's disease – effects of lamotrigine. J Neural Transm 105, 295–303 (1998). https://doi.org/10.1007/s007020050059
Issue Date:
DOI: https://doi.org/10.1007/s007020050059